Vietnam · Delayed Price · Currency is VND Imexpharm Statistics
Total Valuation
Imexpharm has a market cap or net worth of VND 5.39 trillion. The enterprise value is 5.08 trillion.
| Market Cap | 5.39T |
| Enterprise Value | 5.08T |
Important Dates
The next estimated earnings date is Friday, October 16, 2026.
| Earnings Date | Oct 16, 2026 |
| Ex-Dividend Date | Jul 13, 2026 |
Share Statistics
Imexpharm has 154.01 million shares outstanding. The number of shares has decreased by -3.93% in one year.
| Current Share Class | 154.01M |
| Shares Outstanding | 154.01M |
| Shares Change (YoY) | -3.93% |
| Shares Change (QoQ) | +28.09% |
| Owned by Insiders (%) | 0.88% |
| Owned by Institutions (%) | 0.69% |
| Float | 1.48M |
Valuation Ratios
The trailing PE ratio is 17.15 and the forward PE ratio is 15.19.
| PE Ratio | 17.15 |
| Forward PE | 15.19 |
| PS Ratio | 2.32 |
| PB Ratio | 2.30 |
| P/TBV Ratio | 2.38 |
| P/FCF Ratio | 21.43 |
| P/OCF Ratio | 18.72 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.94, with an EV/FCF ratio of 20.20.
| EV / Earnings | 16.17 |
| EV / Sales | 2.19 |
| EV / EBITDA | 8.94 |
| EV / EBIT | 10.87 |
| EV / FCF | 20.20 |
Financial Position
The company has a current ratio of 3.36, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.36 |
| Quick Ratio | 1.91 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 0.34 |
| Debt / FCF | 0.78 |
| Interest Coverage | 33.61 |
Financial Efficiency
Return on equity (ROE) is 16.15% and return on invested capital (ROIC) is 17.77%.
| Return on Equity (ROE) | 16.15% |
| Return on Assets (ROA) | 9.78% |
| Return on Invested Capital (ROIC) | 17.77% |
| Return on Capital Employed (ROCE) | 19.12% |
| Weighted Average Cost of Capital (WACC) | 6.45% |
| Revenue Per Employee | 1.62B |
| Profits Per Employee | 218.61M |
| Employee Count | 1,444 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 1.81 |
Taxes
In the past 12 months, Imexpharm has paid 96.43 billion in taxes.
| Income Tax | 96.43B |
| Effective Tax Rate | 21.11% |
Stock Price Statistics
The stock price has decreased by -32.69% in the last 52 weeks. The beta is 0.41, so Imexpharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.41 |
| 52-Week Price Change | -32.69% |
| 50-Day Moving Average | 43,314.00 |
| 200-Day Moving Average | 49,657.00 |
| Relative Strength Index (RSI) | 17.62 |
| Average Volume (20 Days) | 10,666 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Imexpharm had revenue of VND 2.32 trillion and earned 314.36 billion in profits. Earnings per share was 2,041.17.
| Revenue | 2.32T |
| Gross Profit | 1.11T |
| Operating Income | 467.37B |
| Pretax Income | 456.75B |
| Net Income | 314.36B |
| EBITDA | 568.40B |
| EBIT | 467.37B |
| Earnings Per Share (EPS) | 2,041.17 |
Balance Sheet
The company has 503.49 billion in cash and 195.18 billion in debt, with a net cash position of 308.31 billion or 2,001.88 per share.
| Cash & Cash Equivalents | 503.49B |
| Total Debt | 195.18B |
| Net Cash | 308.31B |
| Net Cash Per Share | 2,001.88 |
| Equity (Book Value) | 2.34T |
| Book Value Per Share | 15,200.82 |
| Working Capital | 1.18T |
Cash Flow
In the last 12 months, operating cash flow was 287.89 billion and capital expenditures -36.30 billion, giving a free cash flow of 251.59 billion.
| Operating Cash Flow | 287.89B |
| Capital Expenditures | -36.30B |
| Depreciation & Amortization | 101.03B |
| Net Borrowing | -209.39B |
| Free Cash Flow | 251.59B |
| FCF Per Share | 1,633.59 |
Margins
Gross margin is 47.99%, with operating and profit margins of 20.12% and 15.51%.
| Gross Margin | 47.99% |
| Operating Margin | 20.12% |
| Pretax Margin | 19.66% |
| Profit Margin | 15.51% |
| EBITDA Margin | 24.47% |
| EBIT Margin | 20.12% |
| FCF Margin | 10.83% |
Dividends & Yields
This stock pays an annual dividend of 500.00, which amounts to a dividend yield of 1.43%.
| Dividend Per Share | 500.00 |
| Dividend Yield | 1.43% |
| Dividend Growth (YoY) | 20.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 21.37% |
| Buyback Yield | 3.93% |
| Shareholder Yield | 5.33% |
| Earnings Yield | 5.83% |
| FCF Yield | 4.67% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 17, 2024. It was a forward split with a ratio of 2.
| Last Split Date | Sep 17, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Imexpharm has an Altman Z-Score of 9.91 and a Piotroski F-Score of 6.
| Altman Z-Score | 9.91 |
| Piotroski F-Score | 6 |